Most of our regulatory coverage so far has focused on strength, battery removability, or flavor naming — rules built around the product's final form. But the pattern behind South Korea's recent move (covered elsewhere on this site) points to a dimension that's easy to overlook: how the nicotine itself is made is becoming a regulatory variable independent of the product's form. This piece lays out that concept on its own, as a cross-market reference.
Two kinds of nicotine, entirely different starting points
Tobacco-derived nicotine: extracted from tobacco leaf through a chemical process — the earliest and most common nicotine source in the vaping industry, and the one most existing regulatory frameworks were originally built around.
Synthetic nicotine: manufactured directly through chemical synthesis, without growing or extracting from tobacco leaf, producing a molecule structurally identical to natural nicotine. This category entered the market in large part because, for a long stretch, it fell outside the legal definition of "tobacco product." If a law defines "tobacco product" as something "derived or extracted from tobacco leaf," synthetic nicotine technically doesn't qualify, and escapes the corresponding regulation — as written.
Two examples that have already written this distinction into law
The US: the FDA only began requiring synthetic nicotine products to file a separate PMTA starting in 2022 — before that, synthetic nicotine products effectively operated under looser regulatory conditions than tobacco-derived ones. That time gap is itself a textbook example of regulation lagging behind product innovation.
South Korea: from April 24, 2026, synthetic nicotine e-liquid is formally brought under the Tobacco Business Act, with all the tax, advertising, and sales-channel restrictions covered elsewhere on this site now applying. This marks the first substantive break from the "tobacco-derived" definition South Korea's framework had used since 1988.
Why this gap tends to widen rather than stay an exception
Both cases follow the same logic: once a regulator recognizes that "synthetic" is being used as a technical path around an existing legal definition, it typically moves to close that gap rather than leave it open indefinitely. The US and South Korea have both already made this move, and the pattern is a reasonable bet to keep spreading — especially in markets whose nicotine regulation text explicitly says "derived from tobacco," which carries a real long-term risk of amendment to fold synthetic nicotine in.
The practical impact on sourcing
This distinction earns its own write-up because it's routinely missed in actual sourcing conversations — supplier quotes and spec sheets almost always list nicotine strength clearly, but whether the nicotine is synthetic or tobacco-derived is often not volunteered at all; buyers usually have to ask.
A few practical takeaways:
- Ask suppliers directly whether a product's nicotine is synthetic or tobacco-derived — don't assume this comes standard with the spec sheet
- If the US is a target market, both sources currently require PMTA authorization, but approval requirements and timelines have historically differed — worth confirming separately
- If South Korea is a target market, both sources face identical rules from April 24, 2026 onward — the distinction no longer matters at the market level there, but understanding the backdrop helps anticipate how Korean regulatory thinking might evolve further
- Watch the wording in other markets' legal text — if a "nicotine product" definition explicitly limits itself to "tobacco-derived," that market is worth tracking, since precedent suggests such definitions eventually get amended
(General information only, not legal advice — consult a lawyer familiar with compliance in your target market before making business decisions.)